Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPONSoR: Spironolactone for Maintenance of Sinus Rhythm in Hypertensive AF with Preserved LVEF
2024-518146-25-00Phase 3Authorised
- Sponsor
- CHU Caen Normandie
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of spironolactone in Atrial fibrillation (AFib) and hypertension (HTN) (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: First documented recurrence of atrial fibrillation within 12 months. Planned start Oct 2024; status: authorised.
02
Drugs
spironolactone
03
Conditions
Atrial fibrillation (AFib)hypertension (HTN)
Beyond the preview
Go deeper on 2024-518146-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518146-25-00.